↓ Skip to main content

Dove Medical Press

Article Metrics

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast

Overview of attention for article published in International Journal of Women's Health, September 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter
video
1 video uploader

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
16 Mendeley
Title
Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
Published in
International Journal of Women's Health, September 2013
DOI 10.2147/ijwh.s39146
Pubmed ID
Authors

Michael DeGregorio, Lin Soe, Gregory Wurz, Chiao-Jung Kao

Abstract

Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor agonist/antagonist, that was recently approved by the US Food and Drug Administration for the treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that affects up to 60% of postmenopausal women. Ospemifene is the first and only nonestrogen compound approved for this indication. Compared with other approved SERMs, such as tamoxifen, toremifene, bazedoxifene, and raloxifene, the estrogen-like effects of ospemifene in the vaginal epithelium are unique. This review first discusses the rationale for developing ospemifene, including its mechanism of action, and then focuses on the clinical development of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Included are discussions of the effects of ospemifene on the endometrium, serum lipids, coagulation markers, bone, and breast cancer. In conclusion, ospemifene is a SERM with a unique estrogen agonist/antagonist tissue profile that was recently approved in the US for the treatment of dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women. Ospemifene warrants further clinical investigation for the treatment and prevention of osteoporosis and breast cancer.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 6%
Unknown 15 94%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 31%
Unspecified 2 13%
Other 2 13%
Student > Bachelor 2 13%
Professor > Associate Professor 2 13%
Other 3 19%
Readers by discipline Count As %
Medicine and Dentistry 6 38%
Nursing and Health Professions 3 19%
Unspecified 2 13%
Psychology 2 13%
Business, Management and Accounting 1 6%
Other 2 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2013.
All research outputs
#9,712,414
of 12,662,735 outputs
Outputs from International Journal of Women's Health
#370
of 500 outputs
Outputs of similar age
#104,815
of 163,917 outputs
Outputs of similar age from International Journal of Women's Health
#20
of 21 outputs
Altmetric has tracked 12,662,735 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 500 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,917 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.